DVA

DaVita Inc. (DVA) sits at the intersection of stable, recurring healthcare demand and acute policy/labor reimbursement pressure. The stock is currently trading around $173.82, with a deeply oversold RSI near 24.2 and a 50-day EMA of $202.73, suggesting the market has repriced the name aggressively after the most recent quarterly report. Below is a data-driven look at what the business actually does, how its financials read, and how the stock has behaved around earnings.

Business profile & competitive position

DaVita is classified in the Healthcare sector, specifically the Medical - Care Facilities industry. Its core business is kidney dialysis: as of December 31, 2025, the company operated 2,657 outpatient dialysis centers in the United States serving approximately 200,500 patients. It also runs integrated kidney care, ancillary services, and an international dialysis footprint of 585 outpatient centers across 14 countries serving roughly 94,500 patients.

The U.S. dialysis operation is the economic engine. According to its most recent 10-K, U.S. dialysis revenues represented approximately 86% of consolidated revenues, and nearly all non-hospital dialysis profits came from commercial payors. That payor concentration is a double-edged structural feature: commercial rates are materially higher than government reimbursement, but the mix also makes costs, pricing negotiations, and utilization trends central to margin stability.

On a profitability basis, DaVita reports a net margin of 6.0%. That is not razor-thin for capital-intensive care facilities, but it is modest, reflecting the fixed-cost nature of running thousands of clinics, staffing specialized labor, and absorbing dialysis supplies. The more jarring figure is ROE of -123.6%. Because ROE divides net income by shareholders’ equity, a deeply negative ROE generally means shareholder equity is negative or near-zero. In DaVita’s case, the company has historically carried substantial leverage and returned capital aggressively, leaving the balance sheet in a position where equity is small or negative. That makes ROE an unreliable stand-alone indicator of operating performance here; the 6.0% net margin is a better place to start when evaluating the core business.

What the data do support is a scale- and reputation-based competitive position. DaVita has been an industry leader in CMS’s Quality Incentive Program for 11 reported years and in the Five-Star Quality Rating System for 10 reported years. That creates at least an operational moat: patient retention, referral relationships, and contract positioning are stronger when quality metrics are consistently high.

Financial posture

DaVita currently commands a market cap of about $11.2 billion and trades at a trailing P/E of 14.9. That valuation sits in a middle range for a mature healthcare services provider—not obviously expensive on earnings, but not a deep-value multiple either. The beta of 0.87 indicates lower volatility than the broader equity market, which is consistent with a business tied to recurring, medically necessary treatments rather than discretionary demand.

The financial profile is one of profitability alongside balance-sheet leverage. The 6.0% net margin and negative ROE combination points to a company that generates positive operating earnings but has a leveraged or equity-light capital structure. For readers benchmarking the name, that means net income and cash flow are the relevant operating metrics, while traditional equity-based returns will look unusual or even alarming unless adjusted for the balance-sheet construction.

There is no bright-line “cheap” or “expensive” verdict from the raw numbers alone. The P/E of 14.9 simply tells you the market is pricing in continued earnings at roughly current levels, with whatever growth, reimbursement, and margin risks investors are already discounting.

Strategic priorities & outlook

DaVita’s own 10-K outlines three broad operational priorities. First, it wants to “reimagine high-quality kidney care” to be more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. Second, it is building integrated care capabilities across the full renal continuum, from chronic kidney disease to end-stage kidney disease to kidney transplant. Third, it is supporting the Comprehensive Kidney Care Contracting model goals of delaying disease progression, promoting home dialysis when appropriate, and incentivizing transplants.

These priorities align with the economics described above. Home dialysis and CKD management are lower-cost settings than in-center hemodialysis, so growing those channels fits the reimbursement pressure that defines the industry. At the same time, delaying disease progression and promoting transplants are medically desirable outcomes, but they also reduce the addressable population for the company’s core dialysis services over very long time horizons. The strategic balancing act is clear: lower cost per patient now, while managing the long-term volume pool.

Macro & geopolitical exposure

As a Medical - Care Facilities company, DaVita is exposed to the reimbursement and regulatory architecture of the countries in which it operates. In the United States, that means Medicare and Medicaid dialysis reimbursement, CMS quality programs, and any legislative or administrative changes to commercial insurance coverage. Because dialysis is a life-sustaining therapy, demand is non-discretionary, but profitability is heavily influenced by the spread between government rates and higher commercial rates.

Labor is another sector-wide factor. Dialysis centers require nurses, technicians, and specialized staff; wage inflation or staffing shortages affect margins predictably. Supply-chain costs for dialysis consumables, equipment, and pharmaceuticals matter as well, especially when margins sit at 6.0%. Internationally, currency translation and local regulatory regimes add another layer of variability to the 14-country footprint. Finally, because the balance sheet is leveraged, changes in interest rates can affect debt-servicing costs and the market’s valuation of leveraged healthcare services companies.

Recent developments

Recent news has centered on the August 2026 earnings report and shifting institutional positioning. On August 5, 2026, Zacks reported that DaVita stock was down in pre-market trading even though the company beat second-quarter earnings expectations, with margins under pressure. The same day, Zacks summarized DaVita’s Q2 earnings call as focusing on clinical-led volume growth—suggesting management is emphasizing patient additions and care quality rather than pricing as the near-term narrative.

On August 6, 2026, Zacks published a separate piece asking whether DaVita is a value stock right now, a question the headline itself frames but does not resolve. Then on August 15, 2026, defenseworld.net reported that Bank of America Corp DE had cut its holdings in DaVita Inc. The combination of a fundamental earnings beat, margin concerns, and reduced institutional ownership likely contributed to the weak price action and the deeply oversold RSI around 24.2.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten earnings expectations six times, for a beat rate of 75%. The average earnings surprise across those quarters has been 2.3%, and the average five-day price move following earnings has been 6.36% to the upside.

That headline average, however, masks considerable dispersion—and the analyst insight here is that beats have not reliably produced follow-through rallies. The most recent four quarters illustrate the point sharply:

• Q2 2026 (reported August 4, 2026): EPS of $4.02 beat the $3.88 estimate by 3.6%, yet the stock fell 17.24% the next day and 21.78% over the following five sessions.
• Q1 2026 (reported May 5, 2026): EPS of $2.87 crushed the $2.41 estimate by 19.1%, driving a 23.46% one-day gain and a 27.7% five-day gain.
• Q4 2025 (reported February 2, 2026): EPS of $3.40 beat the $3.24 estimate by 4.9%, with the stock rising 21.17% the next day and 23.79% over five sessions.
• Q3 2025 (reported October 29, 2025): EPS of $2.51 missed the $3.17 estimate by 20.8%, sending the stock down 6.17% the next day and 4.27% over five sessions.

The average 5-day post-earnings drift of 6.36% is almost entirely attributable to the two large positive reactions in Q1 and Q4 2026; they overshadow the smaller moves and the severe negative drift after the Q2 2026 beat. That means DaVita’s post-earnings price action is better understood as having high variance than as a dependable drift.

Looking ahead, DaVita is scheduled to report next on October 28, 2026, after the market close, with a consensus EPS estimate of $3.58. Given that the last report delivered a beat yet triggered a roughly 22% five-day decline, expectations around the report are likely to be more nuanced than simply “beat means up.” Margin guidance, commercial mix, and volume commentary may matter as much as the headline EPS number.

For a deeper dive into how sell-side analysts and institutional holders are interpreting the reimbursement path, the leverage profile, and the upcoming October 28 report, readers should examine the full institutional verdict on DaVita rather than relying on these summary figures alone.